ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Q2 2026
EPS
-$0.38
est -$0.29
-32.5%
Revenue
$11M
est $13M
-14.6%
ClearPoint Neuro's pivot toward drug delivery readiness ahead of 2027 partner approvals now runs on a tighter clock: cash fell to $29.4 million from $45.9 million at the start of the year. The company also cut full-year 2026 revenue guidance to $48 million to $52 million and missed expectations on both lines as the IRRAS integration lifted operating expenses.
Mentioned: CLPT